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Abstract
Background: The COVID-19 pandemic has disrupted routine measles immunisation and supplementary
immunisation activities (SIAs) in most countries including Kenya. We assessed the risk of measles outbreaks during
the pandemic in Kenya as a case study for the African Region.
Methods: Combining measles serological data, local contact patterns, and vaccination coverage into a cohort
model, we predicted the age-adjusted population immunity in Kenya and estimated the probability of outbreaks
when contact-reducing COVID-19 interventions are lifted. We considered various scenarios for reduced measles
vaccination coverage from April 2020.
Results: In February 2020, when a scheduled SIA was postponed, population immunity was close to the herd
immunity threshold and the probability of a large outbreak was 34% (8–54). As the COVID-19 contact restrictions
are nearly fully eased, from December 2020, the probability of a large measles outbreak will increase to 38% (19–
54), 46% (30–59), and 54% (43–64) assuming a 15%, 50%, and 100% reduction in measles vaccination coverage. By
December 2021, this risk increases further to 43% (25–56), 54% (43–63), and 67% (59–72) for the same coverage
scenarios respectively. However, the increased risk of a measles outbreak following the lifting of all restrictions can
be overcome by conducting a SIA with ≥ 95% coverage in under-fives.
Conclusion: While contact restrictions sufficient for SAR-CoV-2 control temporarily reduce measles transmissibility
and the risk of an outbreak from a measles immunity gap, this risk rises rapidly once these restrictions are lifted.
Implementing delayed SIAs will be critical for prevention of measles outbreaks given the roll-back of contact
restrictions in Kenya.
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Background
The SARS-CoV-2 pandemic has damaged the economy
and disrupted social interaction and important health
services in Kenya and elsewhere [1, 2]. The cumulative
incidence of COVID-19 cases continues to rise in many
parts of Africa suggesting the current mitigation mea-
sures will be maintained or reintroduced for periods at
least until the pandemic peaks [3].
Despite the World Health Organization (WHO) advis-
ory to sustain routine immunisation (RI), vaccine cover-
age temporarily declined in many countries including
Kenya that reports a 33% disruption of RI [4–7]. Follow-
ing guidance from the WHO, all countries suspended
scheduled measles SIAs [6–8]. Measles control in Kenya
is achieved by giving children a first dose of measles-
containing vaccine (MCV1) at 9 months, and a second
dose (MCV2) from 18months. SIAs, first introduced in
2002, are conducted periodically among children < 5
years or < 15 years for accelerated control of measles [9].
Based on the accumulation of susceptible children, the
timing of such campaigns has typically been chosen to
close immunity gaps in time to prevent potentially large
measles outbreaks. A measles SIA originally planned for
2019 was rescheduled for February 2020 due to a short-
fall in funding and postponed again following the
COVID-19 pandemic.
Following identification of the first COVID-19 case on
March 13, 2020, Kenya imposed various mitigation mea-
sures: ban on large gatherings, suspension of inter-
national flights, closure of bars, cessation of movement
from hotspot counties, restriction of restaurant operat-
ing hours, and a nationwide curfew from 7 pm to 5 am.
While it is plausible that these physical distancing and
lock down measures may reduce the risk of measles out-
breaks, they are temporary and may be associated with
rebound risk periods.
The availability of recent measles serological data pro-
vided the opportunity to use Kenya as a case study to es-
timate the impact of reduced measles vaccination
coverage and suspended SIAs due to COVID-19 on the
risk of measles outbreaks.
Methods
This study used a cohort mathematical model that com-
bined measles serological data, local contact patterns,
and vaccination coverage estimates.
Serological data
We estimated measles immunity profile in children
using serum samples collected during serological surveys
among residents of Kilifi Health and Demographic Sur-
veillance System (KHDSS) Kilifi, Kenya [10] for the
Pneumococcal Conjugate Vaccine Impact Study (PCVIS)
[11]. These serosurveys, conducted every 2 years since
2009, target 50 KHDSS randomly selected children in
ten age strata (0, 1, 2, 3, 4, 5, 6, 7, 8–9, and 10–14 years)
and blood samples < 2 ml were collected from partici-
pants. The sample size for the PCVIS serosurveys was
calculated to obtain narrow confidence intervals around
the estimate of prevalence of immune response both
overall and by age-category for each serosurvey year. For
instance, for a proportion of 0.80, the 95% confidence
intervals (CIs) would be 0.77–0.84 overall and 0.69–0.91
in each age stratum.
In the 2019 serosurvey, there were 497 participants
and the blood samples were collected in July (165), Au-
gust (162), September (130), and October (40). We
tested for measles immunoglobulin G (IgG) antibodies
using a fluorescent-bead-based multiplex immunoassay.
Antibody concentrations ≥ 0.12 IU/ml were considered
protective against measles [12].
We assumed these results reflected measles immunity
in Kilifi in August 2019 and assumed 96% of persons >
15 years had protective measles antibodies concentra-
tions, similar to findings in adults in Nairobi in 2007–
2009 [13] (Table 1). We also assumed protection from
maternal immunity was similar to the proportions of the
infants < 9 months old who had protective antibodies.
Vaccination coverage
MCV1 national coverage in Kenya has been between 75
and 80% since its introduction in 1985 [17]. MCV2 was
introduced in Kenya in 2013 and coverage rose up to
45% in 2018 [9]. The last measles SIA in children aged
9 months to 14 years took place in 2016 and achieved
95% coverage [22].
We assumed national MCV1 and MCV2 coverage
were 79% and 45%, respectively, in 2018, and that these
stayed at the same level from August 2019 until the end
of March 2020 when COVID-19 contact restrictions
were introduced in Kenya. From April 2020, we explored
the following routine vaccination coverage scenarios
alongside a suspended SIA.
A. Routine vaccination coverage remained the same
B. Routine vaccination coverage reduced by 15% for
both MCV1 and MCV2
C. Routine vaccination coverage reduced by 50% for
both MCV1 and MCV2
D. Routine vaccination was suspended
Contact matrix
We used an age-mixing matrix which consisted of the
number of contacts between six different age groups.
The matrix was generated from diary studies conducted
in Kilifi, Kenya [21], using a bootstrap of 4000 samples
by randomly sampling n individuals with replacement
from the n participants of the contact survey.
Mburu et al. BMC Medicine           (2021) 19:35 Page 2 of 10
Projecting immunity
We adapted a static cohort model of measles immunity
[23] to estimate age-stratified population immunity pro-
file in Kilifi by combining recent measles serological data
with new vaccine-derived immunity during the predic-
tion period using the local vaccination schedule, MCV1
and MCV2 uptake, and vaccine efficacy. We assumed
waning immunity or additional acquired immunity from
natural exposure, and demographic changes in the short
time frame were negligible. Hence, the key mechanisms
of the projection model were that individuals are born at
a constant rate, gained immunity through vaccination at
the recommended age and at the observed coverage, and
grow older.
In extrapolating immunity for young infants under
9 months old, maternal immunity was assumed to be
the same as the observed data. For ages 9 months to
17 months, immunity was estimated in accordance
with the assumed MCV1 vaccination uptake and a
vaccine effectiveness of 93%. For those ≥ 18 months,
we estimated the immunity based on the assumed up-
take of MCV2 and the same vaccine effectiveness. We
aggregated projected immunity to age groups given by
contact data and weighted each age group according
to population estimates before averaging them to esti-
mate overall immunity. We did not explicitly model
MCV2 delivery but rather assumed that the MCV1
effectiveness is an average of MCV1 and MCV2
efficacy weighted by proportion of children who re-
ceive MCV1 only or both doses. The underlying as-
sumption here was that the same children who
received MCV2 had also received MCV1. We pre-
dicted age-stratified and population-level immunity
until December 2021.
To derive a contact-adjusted estimate for the propor-
tion of the population who are immune to measles, the
predicted age-stratified immunity profile was weighted
by age-stratified social contact patterns observed in
Kilifi. This method has been previously shown to yield
robust projections for measles immunity to transmission
in the population [23].
The herd immunity threshold (HIT) for measles dur-
ing the COVID-19 pandemic was calculated assuming
an R0 of 12 to 18 with a median of 14 [19] and that
COVID-19 prescribed contact restrictions caused a 50%
reduction in measles transmissibility similar to the ob-
served reduction in physical contacts in Kenya [20]. We
also explored a 25% and 75% reduction in measles trans-
missibility in a sensitivity analysis. The HIT is calculated
as 0 = (R0–1)/R0.
Quantitative impact of outbreak risk
We obtained a crude estimate of the outbreak risk using
the predicted immunity and HIT. The probability of a
large outbreak, p, sparked by a single infected individual
was given by p = 1 − (1/R)I0 where I0 is the initial num-
ber infected and R is the effective reproductive number.
R < 1 implies that probability, p, is negative which is de-
fined to be 0 for no outbreak.
The effectiveness of a post-lockdown SIA in reducing
outbreak risk
We assessed the impact of SIAs in two age categories: 9
months to 5 years and 9months to 15 years, by predict-
ing the post-SIA immunity profile and the correspond-
ing risk for a large measles outbreak. We simulated SIAs
in either November 2020, December 2020 or December
2021, assumed a coverage of 95% similar to the most
Table 1 Model parameters. An overview of the key model parameter assumptions and their sources. Parameter ranges are those
used in the sensitivity analyses
Parameter Value (95% quantiles) Source
Vaccine schedule MCV1: 9 months
MCV2: 18 months
[14]
Vaccine effectiveness (beta distributed) MCV1: 85% (80–90%)
+MCV2: 98% (95–100%)
Combined effectiveness 93% (88–96%)
[15, 16]
Age-immunity profile in < 15 years old (bootstrapped from data) Observed in 2019 [11]
Proportion immune among > 15 years old (beta distributed) 96% (90–99%) [13]





Vaccine coverage from April 2020 MCV1 and MCV2 0%, 15%, 50%, or 100%
reduced
Assumption
R0 measles (Log-normally distributed) 14 (12–18) [19]
Reduction in contacts during COVID-19 50% (25% and 75%) [20]
Age demographics From KHDSS in 2019 [10]
Social mixing matrix From 2011/12 [21]
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recent national SIA in 2016 [22], and applied vaccine ef-
ficacy of MCV1. The SIA was simulated by reducing the
age-specific pool of susceptible by the effective coverage
of the SIA.
In simulating the SIA, we used the age-specific pre-
dicted immunity to calculate the age-specific pool of
susceptible at the different time-points. We reduced
this age-specific pool of susceptible in the age-groups
of interest by the effective coverage of the SIA. We
aggregated the results and adjusted the overall crude
immunity using the social contact matrix. Finally, we
calculated the outbreak probability assuming a SIA is
conducted before restrictions are lifted (using the re-
duced HIT based on 50% reduction in contacts) and
assuming an SIA is conducted after restrictions are
lifted (using the normal HIT based on 0% reduction
in contacts).
Uncertainty analyses
We assessed the sensitivity of our findings to uncertainty
inherent in several of our assumptions via probabilistic
re-sampling. We included uncertainty for population im-
munity profile, combined MCV1 and MCV2 vaccine ef-
fectiveness, and MCV1 and MCV2 coverage (Table 1).
As part of each parameter bootstrap, we also boot-
strapped participants of the serological survey and hence
the age-stratified population immunity at the start of the
simulation. We present median estimates including un-
certainty quantified as per the 95% quantiles of the 4000
bootstrap samples.
Sensitivity analyses
We conducted a sensitivity analysis to assess the impact
of a delay in receipt of MCV1 on outbreak probability.
We delayed the age of receipt of MCV1 in our model by
3 months as reported for delayed vaccination in Kilifi
[18] and also by 6 months. We also predicted unadjusted
population immunity in Kilifi and estimated the corre-
sponding probability of a large outbreak.
Results
Measles seroprevalence in Kilifi in late 2019
The proportion of MCV1-eligible children with protect-
ive measles antibody concentrations was high in 2019 as
shown in Fig. 1 and Additional file 1; Table S1. Seventy-
one of 74 (96%) children ≥ 9 years had protective levels.
Similarly, 228 of 237 (96%) 4–8-year-olds were immune.
Among under-fours eligible for MCV1, 145 of 166 (87%)
were immune while one of 20 (0.05%) children under 9
months old, who were ineligible for MCV1, had protect-
ive antibodies.
Age-adjusted immunity
We estimate that in late 2019, population immunity ad-
justed for age-differences in social contacts was 90%
(85–92). Predicted immune proportions were unchanged
in February 2020, at the time of originally planned SIA.
Following the start of COVID-19 pandemic and re-
striction measures that caused a decrease in vaccination
coverage, we estimate that population immunity de-
creased quickly, depending on the extent of reduction in
vaccination coverage. If coverage reduced by 15% from
Fig. 1 Age-stratified population immunity profile. Estimated age-stratified proportion of the Kilifi County population who were immune to
measles infection in August 2019 from data. Antibody concentrations ≥ 0.12 IU/ml were defined as protective. Confidence bounds displayed (in
red) are the 95% quantiles of a nonparametric bootstrap that is used to propagate uncertainty into the modelling framework. MCV1 is
recommended to be administered at 9 months as per the Kenyan immunisation schedule and MCV2 from 18months
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April 2020, the contact-adjusted population immunity
would decline to 88% (85–91) by December 2020 and
87% (84–90) by December 2021. A 50% reduction in
vaccination coverage would lead to a more rapid decline
in this immunity to 87% (83–89) in December 2020 and
85% (81–87) in December 2021(Fig. 2).
Age-adjusted immunity vs herd immunity threshold
A basic reproduction number of 14 (12–18) implies a
HIT of 93% (82–94) and if, as a result of physical distan-
cing, measles transmission is reduced by 25%, 50%, and
75% this HIT drops to 90% (89–93), 86% (83–89), and
71% (67–78) as seen in Additional file 2: Fig. S1. Before
contact restrictions came into effect in April 2020, age-
adjusted immunity was below the HIT: in 99% of simula-
tions this immunity was below the HIT (Additional file 3:
Fig. S1). Reduction in HIT temporarily mitigated the im-
mediate risk for measles outbreak as in April 2020, 94%
of simulations were above the 50% reduced transmission
HIT, 20% were above the 25% reduced HIT, and 100%
of simulations were above the 75% reduced HIT.
Depending on vaccination coverage maintained during
COVID-19 pandemic, population immunity may decline
quickly in young children (< 2 years). By April 2020, age-
adjusted immunity fell below the normal transmission
HIT in all simulations under all the scenarios. (Add-
itional file 3: Fig. S1).
Similarly, the risk of a large measles outbreak from the
introduction of a single infectious individual increased
quickly if routine vaccination coverage declined (Fig. 3).
If in December 2020, measles transmissibility is similar
to pre-COVID-19 levels and routine measles coverage
since April 2020 reduced by 15%, 50%, or 100%, we esti-
mate the probability for a large measles outbreak as 38%
(19–54), 46% (30–59), and 54% (43–64), respectively, in
the age-adjusted analysis. By December 2021, this risk
would increase to 43% (25–56), 54% (43–63), and 66%
(59–72), respectively. The probability of a large measles
outbreak was much lower if measles transmissibility re-
duced by 25%, 50% and 75% (Additional file 4: Fig. S1).
In December 2020, if routine measles coverage since
April 2020 reduced by 50%, we estimate the probability
of a large measles outbreak as 28% (7–45), 0% (0–18),
and 0%(0–0) assuming a 25%, 50%, and 75% reduction
in transmission.
Effectiveness of a SIA
A SIA in 9-month to 5-year-old children or 9-months to
15-year-olds both during and immediately after lifting
transmission-reducing COVID-19 restrictions can sub-
stantially reduce outbreak risk (Fig. 4).
If measles vaccine coverage declines by 15%, 50%, or
100% from April 2020, a post lockdown SIA delivered to
children 9 months to 5 years old in December 2020 with
Fig. 2 Monthly projected age-adjusted immunity profiles from September 2019 to December 2021. The changes in coverage took effect in April
2020. The black dotted line shows the herd immunity threshold for measles before the COVID-19 physical distancing measures, 0.93[0.92-0.94]
and the brown dotted line shows the herd immunity threshold during COVID-19 physical distancing measures, 0.86[0.83–0.89], assuming the
lockdown measures are still in effect. The bold lines and shaded region in each scenario, i.e. a. no reduction, b. 15% reduction, c. 50% reduction,
and d. 100% reduction, indicate the median estimates and the uncertainty of the predicted immunity quantified as the 95% quantiles of the
bootstrap analysis. There was a quick decline of predicted immunity over the study period that was based on assumed reduction in
routine coverage
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Fig. 3 Probability of a large measles outbreak sparked by a single infected individual. Outbreak probability was calculated using the predicted
immunity and herd immunity threshold before (red) and during (green) COVID-19 movement restriction measures. Zero probability indicates no
possibility of an outbreak. The bold lines and shaded region in each scenario, i.e. a. no reduction, b. 15% reduction, c. 50% reduction, and d.
100% reduction, indicate the median estimates of outbreak risk and the uncertainty quantified as the 95% quantiles of the bootstrap analysis. The
risk of a large measles outbreak from the introduction of a single infectious individual increased quickly based on the level of impairment of
routine vaccination coverage
Fig. 4 Probability of a single infectious person seeding a large outbreak before (none) and after implementing a SIA in children 9 months to 5
years old (U5) and in 9 months to 15 years old (U15) at different timepoints post-lockdown (normal transmission) and during lockdown (50%
transmission reduction). Outbreak probability was calculated by comparing the proportion immune with the herd immunity threshold. The
shaded area is the median estimate of the outbreak risk and the error bars indicate the uncertainty in outbreak risk quantified as the 95%
quantiles of the bootstrap analysis. In all the scenarios, i.e. a. No reduction, b. 15% reduction, c. 50% reduction, and d. 100% reduction, the risk of
a large measles outbreak would be largely mitigated through delivery of a SIA among children < 5 years old or < 15 years old
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95% coverage would reduce the risk of an outbreak to
0% (0–17), 0% (0–20), and 0% (0–22), respectively, in
age-adjusted analysis. A similar SIA would reduce the
risk of an outbreak to 0% in all the scenarios assuming a
50% reduction in contacts in December 2020 (Fig. 4).
Even if RI coverage is low through to December 2021,
the risk for a large measles outbreak would be mitigated
through an SIA for under-fives if delivered as soon as
possible (Additional file 5: Fig. S1).
Impact of delayed vaccination on outbreak probability
A 3-month and 6-month delay in the receipt of MCV1
in age-eligible children caused a marginal increase in the
risk of a large measles outbreak (Additional file 6: Fig.
S1). This increase in outbreak risk associated with a
delay in receipt of MCV1 was also evident for different
assumptions of transmission reduction during lockdown
(Additional file 6: Fig. S1).
Crude population immunity
The predicted crude population immunity was slightly
higher compared to age-adjusted immunity but followed
the same declining trend over time (Additional file 7:
Fig. S1). Before contact restrictions came into place, 73%
of simulations were below the HIT and by October 2020
and July 2020, this immunity fell below the HIT in more
than 95% of simulations under scenario C and D re-
spectively (Additional file 8: Fig. S1).
Discussion
Our analysis suggests a decline in population immunity
during COVID-19 pandemic will result in an increased
risk of a measles outbreak depending on the extent to
which routine vaccination coverage is reduced. We esti-
mated the probability of a large measles outbreak from
the introduction of a single infectious individual to be
38% (19–54), 46% (30–59), and 54% (43–64) in Decem-
ber 2020 assuming a 15%, 50%, or 100% reduction in
routine measles vaccination coverage respectively since
April 2020. This risk, which will increase to 43% (25–
56), 54% (43–63), and 67% (59–72) by December 2021,
will be greatly reduced if a SIA among children < 5 years
old is conducted before or immediately after all COVID-
19-related restrictions on physical contact are lifted.
We based our analysis on an immunity model that
combined serological data and age-specific mixing pat-
terns in Kenya. Combining the two is a better strategy
for predicting outbreaks as opposed to using immunity
profiles alone as it allows adjustment of overall immun-
ity by taking into account the contribution of each age-
group to transmission [23].
As there is considerable uncertainty in actual reduc-
tion of routine vaccination uptake, we predicted popula-
tion immunity for scenarios of routine vaccination
coverage since April 2020, i.e. 15%, 50%, and 100% re-
ductions, and the corresponding outbreak risk. Our as-
sumption of 15% reduction in vaccine coverage rates is
based on reduction in vaccine clinic visits in Kilifi
County (DHIS2 Routine Report) while the 50% reduc-
tion lies in the range of reported disruption in vaccin-
ation services from WHO immunisation pulse poll [6].
We assumed a 50% reduction in measles transmissibility
given that COVID-19 mitigation measures implemented
on 25th March 2020 were reported to have reduced so-
cial contacts and disease transmission by the same mar-
gin [20]. Although some restriction measures remain in
place, e.g. nationwide curfew, others like the partial lock-
down have since been eased and ban on international
flights was lifted on 1st August 2020. While the assump-
tion of a 50% reduction in measles transmission was ap-
plicable at the beginning of the epidemic due to
stringent measures imposed, current herd immunity
threshold may be much higher than originally assumed
but still lower than pre-COVID-19 threshold.
To account for the uncertainty in measles transmissi-
bility during lockdown, we explored two other scenarios,
25% and 75% reduction in measles transmission in a
sensitivity analysis. We found that a 75% reduction in
measles transmission would result to zero outbreaks in
all the scenarios during the entire study period, which
was much lower compared to the outbreak probability
in our baseline analysis. A 25% reduction in measles
transmission resulted to a much higher probability of
measles outbreak compared to our baseline analysis. For
instance, in December 2020, the estimated outbreak risk
was 28% (7–45) compared to 0% (0–18) in our baseline
analysis assuming a 50% reduction in routine vaccination
coverage.
In the calculation of a quantitative impact of outbreak
risk, our estimate of the probability of a large outbreak
was based on the introduction of a single infectious indi-
vidual in a population where there is hardly any measles
circulation. Based on our results, the outbreak probabil-
ity would be much higher and severe if multiple cases
were introduced.
SIAs in Kenya are generally conducted every 2–4 years
and provide a second opportunity for vaccination in
children regardless of their vaccination history and are
ideally timed to close immunity gaps arising from the ac-
cumulation of susceptible and vaccine failures [24]. They
have been shown to be effective in increasing immunisa-
tion equity by reaching children from poor households
[25]. In February 2020, at the time of the planned na-
tional SIA, we estimated that 90% (85–92) of the popula-
tion were immune after adjusting for age-differences in
social contact. This immunity which was equivalent to a
34% (8–54) probability of a large outbreak suggests the
SIA would have been timely in closing immunity gaps.
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The risk of an outbreak which was accelerated by im-
munity gaps arising in children who missed their rou-
tinely delivered MCV1 and MCV2 continued to increase
in subsequent months following the start of COVID-19
and by December 2020, the estimated risk had increased
to 38% (19–54), 46% (30–59), and 54% (43–64) assum-
ing a 15%, 50%, and 100% reduction in measles vaccin-
ation coverage respectively. Based on limited
information on additional reductions in vaccination
coverage as the pandemic progressed in Kenya’s de-
volved counties and marked reduction in vaccination
services in Kenya in May 2020 compared to January and
February 2020 reported in the second WHO immunisa-
tion poll, it is highly probable most areas will experience
an outbreak risk of 46% (30–59) corresponding to a 50%
reduction in routine coverage.
Assuming all COVID-19 restrictions remain in place,
the risk of outbreaks would only be experienced in the
suspended RI scenario in 2021. The severity and timing
of these outbreaks would be largely reduced if a measles
vaccine campaign is delivered but it will also depend on
time delay of catch-up campaigns and speed at which a
campaign can be organised. In December 2020 for in-
stance, a SIA would reduce outbreak risk to zero in all
scenarios with an upper bound risk of 15% while in De-
cember 2021, outbreak risk would reduce to zero with
an upper bound risk of 25% after delivery of SIA.
The current disruption to vaccination services will
cause further delays to vaccination, which is a challenge
even in normal circumstances. We had previously re-
ported consistently poor timeliness of MCV1 vaccination
across 6 different birth-cohorts (2011–2016) in Kenya
[18]. Here, a delay in age of MCV1 by 3months resulted
in a marginal increase in outbreak risk. For instance, as-
suming a 50% reduction in routine vaccination, a delay
in vaccination would see the risk increase from 46%
(30–59) to 53% (40–64) by the end of the year. This reit-
erates the importance of timeliness in administration of
vaccines in children as even a slight delay may cause
considerable immunity gaps.
Our results emphasise the importance of maintaining
high RI coverage during this pandemic because the ben-
efits of sustaining RI services far outweighs the risks of
any excess COVID-19 deaths that may arise from vac-
cination clinic visits [5]. Due to the highly infectious na-
ture of measles, massive outbreaks following disruptions
to health care systems and reduced MCV1 coverage are
typical. Following the West Africa Ebola outbreak in
2014–2015, Liberia, Sierra Leone, and Guinea reported
more than a 25% reductions in MCV1 coverage [26, 27].
Reported cases also occurred in a lower age group com-
pared to pre-Ebola period suggesting accumulation of
susceptible children who missed their vaccine doses was
a key contributor. Immunity gaps continued to be felt in
these countries 2 years later even after successful imple-
mentation of SIAs.
Recently, measles outbreaks have been reported in five
counties in Kenya [28] even with COVID-19 restrictions
which suggests an adverse synergistic interaction be-
tween pre-existing gaps of susceptibility due to lower
vaccination coverage in some counties (compared to na-
tional estimates) and a precipitous drop in RI coverage
during this period. These outbreaks and our results are
well aligned with recent Kenya measles risk assessment
report by the Measles and Rubella Initiative, and recent
WHO guidance on catch-up vaccination to close the im-
munity gaps caused by the COVID-19 pandemic.
As expected, majority of vaccine eligible children had
protective antibody concentrations against measles while
only one of 20 (0.05%) infants under 9 months old had
protective levels. This suggests that there is an extended
period of susceptibility in young infants probably a con-
sequence of rapid decay of maternally acquired antibody.
This will require further investigation in Kenya. How-
ever, this phenomenon has been previously reported in
areas where maternal immunity is increasingly from im-
munisation rather than natural infection [29].
Our analysis was based on data from a rural area in
the African region. Although these results are largely
representative of rural areas in measles endemic settings,
they may vary in an urban setting especially as measles
susceptibility profiles have been shown to vary across
urban and rural settings mainly due to heterogeneity in
vaccination coverage and the different mixing patterns
between and within age-groups.
A key strength of our study is the availability of recent
serological data which provides an excellent means of
directly estimating levels of population protection
against infection and can also be used to guide post-
COVID-19 SIAs. In addition, the availability of an age-
mixing matrix from the same area allowed us to estimate
overall immunity by taking into account the level of con-
tact between different age-groups.
Our study has a few limitations. Population immunity
was only available for children < 15 years, but we varied
observed immunity estimates in adults from a previous
study in our model which resulted in a slight shift in
overall immunity. Our results showing SIAs conducted
in under-fives will mitigate the risk of measles outbreak
risk are based on the assumption that majority (96%) of
the older age groups have measles immunity. Suscepti-
bility gaps in this older age-groups will require SIAs for
a wider age range (e.g. 9 months to 15 years) to close
population immunity gaps and reduce the outbreak risk.
The serological data estimates and the mixing matrix
used in our study may not be fully representative of the
country although we utilised national estimates of vac-
cination coverage, which was the main driver of
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predicted immunity. We did not explicitly model MCV2
delivery but assumed the overall effectiveness was an
average of MCV1 and MCV2 efficacy weighted by the
proportion of children who either receive MCV1 only or
both doses. Finally, there is some uncertainty around the
actual reduction in transmission due to variability in
compliance with physical distancing measures in place.
However, we accounted for uncertainty by varying both
the reduction in transmission and the R0.
Conclusions
Measles SIA originally scheduled for February 2020 in
Kenya would have been well-timed as population im-
munity was below herd immunity threshold. Interrup-
tions to RI since the start of COVID-19 pandemic
restrictions in Kenya have now widened the measles im-
munity gap, but the associated risk of large measles out-
breaks were partially mitigated by COVID-19 contact
restrictions in place. As these measures have almost
been fully lifted, we estimate that measles outbreak risks
will dramatically increase, and an immediate SIA will be
required to close measles immunity gaps.
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